The Swiss city of Lausanne is perhaps best known as a hub of international sport, but what many outsiders may not realize is that it’s also one of Switzerland’s biggest…
Swiss Asceneuron has received regulatory approval to start its first Phase I trial of ASN120290, which is indicated for the treatment of dementia. Asceneuron was founded in 2012 as a spin-off…
The fight against Alzheimer's with the World Health Organization and the G8 Dementia Summit rallies a collective of biotech industry specialists also wanting in on the battle front. The latest…
Takeda Cambridge (the UK subsidiary of global biotech Takeda Pharmaceuticals) will now collaborate with University College London's Institute for Neurology and their NHS teaching hospital to search for novel gene…
Paris based Sofinnova continues to invest in the Alzheimer's fight, with a €27.5M pot given to Swiss Asceneuron (originally a spin-off from Merck-Serono). Sofinnova therefore joins other investors such as…